Overall, PD-L1 tumor expression is considered an inefficient biomarker, currently used as a “surrogate” for predicting cancer patients who are more likely to benefit from anti-PD-1/PD-L1 therapy [29, 30, 32, 33, 67]. This evidence concerns the gene PDCD1 and neoplasm.